Pathology & Oncology Research

, Volume 25, Issue 2, pp 697–701 | Cite as

Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid

  • Li DingEmail author
  • Yunhui Jiang
  • Wan Yang
Original Article


To observe the expression of P53, CyclinD1, Ki-67, Galectin-3, COX-2, Bcl-2 and approach their contribution on assessing the invasive potential for Hurthle cell tumors. Seventy-three cases of Hurthle cell tumor were collected for immunohistochemistry staining. The patients were followed up with 8 months to 5 years. Tumors were divided into four grades according to invasion and diameter:(1) extremely low risk (27 cases that less than 2 cm and without invasion), (2) low risk (18 cases that within 2–3.9 cm and without invasion), (3) moderate risk (21 cases that achieve 4 cm and without invasion), (4) high risk (7 cases that with invasion of capsule/vessel in spite of the diameter). Immunostaining presented that all 73 cases were positive with Galectin-3, COX-2 and Bcl-2. For each group, P53 positive were 29.6%, 55.6%, 90.5%, 100.0%; CyclinD1 stained with 7.4%,22.2%,52.4%,100.0% and Ki-67 were 0.0%,5.6%,9.5%,28.6%, respectively. The higher risk of tumor, the more cases that positive expressed P53 and CyclinD1. After following up within 49 patients, two of the recurring cases were positive with P53 and CyclinD1 and one of which was also highly expressed Ki-67. Detecting P53, CyclinD1 and Ki-67 might provide reference for invasive potential assessment with Hurthle cell tumors but not Galectin-3, COX-2 and Bcl-2.


Hurthle cell tumors Immunohistochemistry P53 CyclinD1 Ki-67 



Thanks to all the colleagues in our department for their support.

Authors Contribution

Ding Li:design and specimen collecting; Jiang Yunhui:pathology diagnosis and specimen collecting; Yang Wan:operate a immunostaining.

Compliance with Ethical Standards

Competing Interests

Each of the author has approved the final version of the manuscript and reports no conflicts of interest.


  1. 1.
    Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DHY, Shaha AR, Shah JP, Brennan MF, Cordon-Cardo C, Ghossein R (2002) Clinical significance of molecular expressing profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays [J]. Am J Pathol 160(1):175–183CrossRefGoogle Scholar
  2. 2.
    Vogrin A, Besic H, Besic N, Music MM (2016) Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms [J]. Radiol Oncol 50(3):269–273CrossRefGoogle Scholar
  3. 3.
    Ahmadi S, Stang M, Jiang XS, Sosa JA (2016) Hürthle cell carcinoma: current perspectives [J]. Onco Targets and Therapy 9:6873–6884CrossRefGoogle Scholar
  4. 4.
    Ernaga Lorea A, Migueliz Bermejo I, Anda Apinaniz E et al (2018) Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma [J]. Endocrinol Diabetes Nutr 65(3):136–142CrossRefGoogle Scholar
  5. 5.
    Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH (2008) Tumor size predicts maligant potential in Hurthle cell neoplasms of the thyroid [J]. World J Surg 32(5):702–707CrossRefGoogle Scholar
  6. 6.
    Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K (2001) Hurthle cell tumor of the thyroid: analysis of 188 cases [J]. World J Surg 25(9):1160–1163CrossRefGoogle Scholar
  7. 7.
    Ding L, Zou X, Yang W et al (2016) Analyze two cases of encapsulated papillary oncocytic neoplasms (EPONs) of the thyroid [J]. Int J Clin Exp Pathol 9(7):7493–7497Google Scholar
  8. 8.
    Ristevska N, Stojanoski S, Gjorceva DP (2015) Appearance of Hürthle cell carcinoma soon after surgical extirpation of Hürthle cell adenoma and follicular adenoma of the thyroid gland [J]. Radiol Oncol 49(1):26–31CrossRefGoogle Scholar
  9. 9.
    Chao TC, Lin JD, Chen MF (2005) Surgical treatment of Hurthle cell tumors of the thyroid [J]. World J Surg 29(2):164–168CrossRefGoogle Scholar
  10. 10.
    Besic N, Hocevar M, Zgajnar L et al (2006) Aggressiveness of therapy and prognosis of patients with Hurthle cell papillary thyroid carcinoma [J]. Thyroid 16(1):67–72CrossRefGoogle Scholar
  11. 11.
    Anila KR, Nayak N, George PS, Jayasree K (2018) Cytomorphologic spectrum of Hurthle cell lesions of thyroid: a study of 54 cases [J]. Gulf J Oncolog 1(26):6–10Google Scholar
  12. 12.
    Krhin B, Goricar K, Gazic B, Dolzan V, Besic N (2016) Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma [J]. Radiol Oncol 50(3):289–296CrossRefGoogle Scholar
  13. 13.
    Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H (2008) Older age and larger tumor size predict malignancy in hurthle cell neoplasms of the thyroid [J]. Ann Surg Oncol 15(10):2842–2846CrossRefGoogle Scholar
  14. 14.
    Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S (2015) Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration [J]. PLoS One 10(3):e0122308CrossRefGoogle Scholar
  15. 15.
    Petric R, Gazic B, Goricar K et al (2016) Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma [J]. Int J Endocrinol 8945247:2016Google Scholar
  16. 16.
    Monaco M, Chiappetta G, Aiello C et al (2014) CBX7 expression in Oncocytic thyroid neoplastic lesions (Hürthle cell adenomas and carcinomas) [J]. Eur Thyroid J 3(4):211–216Google Scholar
  17. 17.
    Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG (2018) Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma [J]. Cancer Cell 34(2):242–255CrossRefGoogle Scholar
  18. 18.
    Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, Patsouris E, Theocharis S (2016) Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions [J]. Pathol Oncol Res 22(1):189–196CrossRefGoogle Scholar
  19. 19.
    Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M (2006) Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors [J]. Endocr Pathol 17(1):53–60CrossRefGoogle Scholar
  20. 20.
    Sumana BS, Shashidhar S, Shivarudrappa AS (2015) Galectin-3 immunohistochemical expression in thyroid neoplasms [J]. J Clin Diagn Res 9(11):EC07–EC11Google Scholar
  21. 21.
    Saleh HA, Jin B, Barnwell J, Alzohaili O (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular derived thyroid nodules [J]. Diagn Pathol 5:9CrossRefGoogle Scholar
  22. 22.
    Sun L, Wei X, Liu X, Zhou D, Hu F, Zeng Y, Sun Y, Luo S, Zhang Y, Yi XP (2016) Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma [J]. Tumour Biol 37(4):4689–4697CrossRefGoogle Scholar
  23. 23.
    Liang M, Zhao J (2018) Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis [J]. Eur Rev Med Pharmacol Sci 22(16):5134–5139Google Scholar
  24. 24.
    Ru Y, Chen XJ, Zhao ZW, Zhang PF, Feng SH, Gao Q, Gao SG, Feng XS (2017) CyclinD1 and p57kip2 as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma [J]. Oncotarget 8(43):73860–73870CrossRefGoogle Scholar
  25. 25.
    Malmstrom PU, Hemdan T, Segersten U (2017) Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer [J]. Urol Oncol 35(8):532.e1–532.e6CrossRefGoogle Scholar
  26. 26.
    Mu N, Juhlin CC, Tani E, Sofiadis A, Reihnér E, Zedenius J, Larsson C, Nilsson IL (2018) High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma [J]. Endocrine 61(2):293–302CrossRefGoogle Scholar
  27. 27.
    Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV (2000) Pathologic features, proliferative activity, and CyclinD1 expression in Hurthle cell neoplasms of the thyroid [J]. Mod Pathol 13(2):186–192CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  1. 1.Department of Pathologythe First People’s Hospital of JingmenJingmenChina
  2. 2.Department of Pathologythe Second People’s Hospital of JingmenJingmenChina

Personalised recommendations